Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-26T13:03:46.311Z Has data issue: false hasContentIssue false

Chapter 12 - Neuroprotection for Acute Brain Ischaemia

from Part III - Acute Treatment of Ischaemic Stroke and Transient Ischaemic Attack

Published online by Cambridge University Press:  15 December 2020

By
Nerses Sanossian  and
Jeffrey L. Saver
Edited by
Jeffrey L. Saver  and
Graeme J. Hankey
Jeffrey L. Saver
Affiliation:
David Geffen School of Medicine, University of Ca
Graeme J. Hankey
Affiliation:
University of Western Australia, Perth
Get access

Summary

More than 20,000 patients have participated in clinical trials of more than 100 neuroprotective therapies, but no study has provided convincing evidence of benefit. Several improvements to the rigor of preclinical agent qualification have been identified to increase the likelihood of success in human clinical trials: stringent randomization and blinding techniques to mitigate observer bias; assessment in in time periods achievable in the clinical setting; testing in older animals with comorbidities; and robust and reproducible benefit magnitudes. Human clinical trials should start agents hyperacutely, in the first minutes and hours after onset, when treatment effect would be maximal; target enrolment of patients likely to have transient rather than permanent ischaemic exposure; and use factorial and platform trial designs that would permit efficient testing of combinations of agents able to block multiple ischaemic injury-mediating pathways concurrently, including both anti-necrotic and anti-apoptotic interventions. For agents that allow cells to endure ischaemic stress, human trial delivery approaches include: prehospital initiation; initiation immediately upon brain imaging in patients destined for endovascular intervention; and initiation at outside hospitals in patients undergoing transfer to a neurothrombectomy center. For agents that mitigate reperfusion injury, treatment start before or concurrent with reperfusion, including intra-arterial administration via catheter immediately after endovascular thrombectomy, should be pursued.

Keywords

Neuroprotectionhypothermiaanti-oxidantapoptosisreperfusion injuryuric acidischaemic cascadeexcitotoxicitystatinsmanagementtreatment
Type
Chapter
Information
Stroke Prevention and Treatment
An Evidence-based Approach
 , pp. 214 - 238
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aerden, LA, Kessels, FA, Rutten, BP, Lodder, J, Steinbusch, HW. (2004). Diazepam reduces brain lesion size in a photothrombotic model of focal ischemia in rats. Neurosci Lett, 367(1), 76–8.CrossRefGoogle Scholar
Arrich, J, Holzer, M, Havel, C, Müllner, M, Herkner, H. (2016). Hypothermia for neuroprotection in adults after cardiopulmonary resuscitation. Cochrane Database Syst Rev, 2. CD004128. doi:10.1002/14651858.CD004128.pub4.Google Scholar
Bardutzky, J, Shen, Q, Henninger, N, Bouley, J, Duong, TQ, Fisher, M. (2005). Perfusion and diffusion imaging in acute focal cerebral ischemia: temporal vs. spatial resolution. Brain Res, 1043, 155–62.Google Scholar
Bath, PM, Iddenden, R, Bath, FJ, Orgogozo, JM; Tirilazad International Steering Committee. (2001). Tirilazad for acute ischaemic stroke. Cochrane Database Syst Rev, 4. CD002087.Google Scholar
Bath, PMW, Krishnan, K, Appleton, JP. (2017). Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke. Cochrane Database Syst Rev, 4. CD000398. doi:10.1002/14651858.CD000398.pub2.CrossRefGoogle ScholarPubMed
Bath, PM, Woodhouse, L, Krishnan, K, Anderson, C, Berge, E, Ford, GA, et al. (2016). Effect of treatment delay, stroke type, and thrombolysis on the effect of glyceryl trinitrate, a nitric oxide donor, on outcome after acute stroke: a systematic review and meta-analysis of individual patients from randomised trials. Stroke Res Treat, 9706720. doi:10.1155/2016/9706720.CrossRefGoogle Scholar
Belayev, L, Liu, Y, Zhao, W, Busto, R, Ginsberg, MD. (2001). Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke, 32, 553–60.Google Scholar
Bennett, MH, Weibel, S, Wasiak, J, Schnabel, A, French, C, Kranke, P. (2014). Hyperbaric oxygen therapy for acute ischaemic stroke. Cochrane Database Syst Rev, 11. CD004954. doi:10.1002/14651858.CD004954.pub3.Google Scholar
Blanco, M, Nombela, F, Castellanos, M, Rodriguez-Yanez, M, Garcia-Gil, M, Leira, R, et al. (2007). Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology, 69, 904–10.CrossRefGoogle ScholarPubMed
Candelise, L, Ciccone, A. (2001). Gangliosides for acute ischaemic stroke. Cochrane Database Syst Rev, 4. CD000094.Google Scholar
Chamorro, A, Amaro, S, Castellanos, M, Segura, T, Arenillas, J, Marti-Fabregas, J, et al. (2014). Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol, 13(5), 453–60.Google Scholar
Chandra, B. (1995). A new form of management of stroke. J Stroke Cerebrovasc Dis, 5, 241–3.CrossRefGoogle ScholarPubMed
Dávalos, A, Alvarez-Sabin, J, Castillo, J, Diez-Teiedor, E, Ferro, J, Martinez-Vila, E, et al. (2012). Citicoline in the treatment of acute ischaemic stroke: an international, randomized, multicenter, placebo-controlled study (ICTUS) trial. Lancet, 380(9839), 349–57.CrossRefGoogle ScholarPubMed
Davis, SM, Pennypacker, KR. (2017). Targeting antioxidant enzyme expression as a therapeutic strategy for ischemic stroke. Neurochem Int, 107, 23–32.Google Scholar
Dhar, R, Misra, H, Diringer, MN. (2017). SANGUINATE™ (pegylated carboxyhemoglobin bovine) improves cerebral blood flow to vulnerable brain regions at risk of delayed cerebral ischemia after subarachnoid hemorrhage. Neurocrit Care, 27, 341–9.CrossRefGoogle ScholarPubMed
Diener, HC, Lees, KR, Lyden, P, Grotta, J, Davalos, A, Davis, SM, et al. (2008). NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II trials. Stroke, 39, 1751–58.CrossRefGoogle ScholarPubMed
Doyle, KP, Simon, RP, Stenzel-Poore, MP. (2008). Mechanisms of ischemic brain damage. Neuropharmacology, 55, 310–18.Google Scholar
Emberson, J, Lees, KR, Lyden, P, Blackwell, L, Albers, G, Bluhmki, E, et al.; Stroke Thrombolysis Trialists’ Collaborative Group. (2014). Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet, 384, 1929–35.Google Scholar
England, TJ, Hedstrom, A, O’Sullivan, S, Donnelly, R, Barrett, DA, Sarmad, S, et al. (2017). RECAST (Remote Ischemic Conditioning After Stroke Trial): a pilot randomized placebo controlled phase II trial in acute ischemic stroke. Stroke, 48 , 1412–1415.CrossRefGoogle Scholar
Enlimomab Acute Stroke Trial Investigators. (2001). Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology, 57, 1428–34.Google Scholar
Fagan, SC, Waller, JL, Nichols, FT, Edwards, DJ, Pettigrew, LC, Clark, WM, et al. (2010). Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke, 41(10), 2283–7.CrossRefGoogle Scholar
Fisher, M, Feuerstein, G, Howells, DW, Hurn, PD, Kent, TA, Savitz, SI, et al; STAIR Group. (2009). Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke, 40, 2244–50.Google Scholar
Garry, PS, Ezra, M, Rowland, MJ, Westbrook, J, Pattinson, KT. (2015). The role of the nitric oxide pathway in brain injury and its treatment – from bench to bedside. Exp Neurol, 263, 235–43.Google Scholar
Hess, DC, Blauenfeldt, RA, Andersen, G, Hougaard, KD, Hoda, MN, Ding, Y, Ji, X. (2015). Remote ischaemic conditioning – a new paradigm of self-protection in the brain. Nat Rev Neurol, 11, 698–710.Google Scholar
Heiss, WD. (2011). The ischemic penumbra: correlates in imaging and implications for treatment of ischemic stroke. Cerebrovasc Dis, 32, 307–20.Google Scholar
Heiss, WD, Thiel, A, Grond, M, Graf, R. (1999). Which targets are relevant for therapy of acute ischemic stroke? Stroke, 30, 1486–9.Google Scholar
Hill, M, Martin, RH, Mikulis, D, Wong, JH, Silver, FL, Terbrugge, KG, et al. (2012). Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol, 11, 942–50.CrossRefGoogle ScholarPubMed
Hong, K-S, Lee, M, Lee, SH, Hao, Q, Liebeskind, D, Saver, JL. (2011). Acute stroke trials in the 1st decade of the 21st century. Stroke, 42, e314.Google Scholar
Horn, J, De Haan, RJ, Vermeulen, M, Limburg, M. (2001). Very Early Nimodipine Use in Stroke (VENUS): a randomized, double-blind, placebo-controlled trial. Stroke, 32, 461–5.Google Scholar
Hougaard, KD, Hjort, N, Zeidler, D, Sorensen, L, Norgaard, A, Hansen, TM, et al. (2014). Remote ischemic perconditioning as an adjunct therapy to thrombolysis in patients with acute ischemic stroke. Stroke, 45, 159–167.Google Scholar
Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. (2004). Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet, 363, 439–45.Google Scholar
Kennedy, J, Hill, MD, Ryckborst, KJ, Eliasziw, M, Demchuk, AM, Buchan, AM; FASTER Investigators. (2007). Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol, 6, 961–69.Google Scholar
Kohler, E, Prentice, DA, Bates, TR, Hankey, GJ, Claxton, A, van Heerden, J, et al. (2013). Intravenous minocycline in acute stroke: a randomized, controlled pilot study and meta-analysis. Stoke, 44, 2493–9.Google Scholar
Krams, M, Lees, KR, Hacke, W, Grieve, AP, Orgogozo, JM, Ford, GA; ASTIN Study Investigators. (2003). Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke, 34, 2543–8.Google Scholar
Kurisu, K, Yenari, MA. (2018). Therapeutic hypothermia for ischemic stroke; pathophysiology and future promise. Neuropharmacology, 134(Pt B), 302-9. pii: S0028-3908(17)30392–1. doi:10.1016/j.neuropharm.2017.08.025.CrossRefGoogle ScholarPubMed
Lapchak, PA, Zhang, JH, Noble-Haeusslein, LJ. (2013). RIGOR guidelines: escalating STAIR and STEPS for effective translational research. Transl Stroke Res, 4, 279–85.Google Scholar
Liu, J, Wang, L-N. (2014). Gamma aminobutyric acid (GABA) receptor agonists for acute stroke. Cochrane Database Syst Rev, 8. CD009622. doi:10.1002/14651858.CD009622.pub3.Google Scholar
Lyden, P, Hemmen, T, Grotta, J, Rapp, K, Ernstrom, K, Rzesiewicz, T, et al. (2016). Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2). Stroke, 47, 2888–95.CrossRefGoogle ScholarPubMed
Lyden, P, Shuaib, A, Ng, K, Levin, K, Atkinson, RP, Rajput, A, et al.; CLASS-I/H/T Investigators. (2002). Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results. Stroke, 33(1), 122–8.Google Scholar
Marehbian, J, Greer, DM. (2017). Normothermia and stroke. Curr Treat Options Neurol, 19, 4. doi:10.1007/s11940-017-0437-6.Google Scholar
Martin, RH, Yeatts, SD, Hill, MD, Moy, CS, Ginsberg, MD, Palesch, YY, ALIAS Parts 1 and 2 and NETT investigators. (2016). ALIAS (Albumin in Acute Ischemic Stroke) trials: analysis of the combined data from parts 1 and 2. Stroke, 47, 2355–9.Google Scholar
Montaner, J, Bustamante, J, García-Matas, S, Martinez-Zabaleta, M, Jimenez, C, de la Torre, J, et al. (2016). Combination of thrombolysis and statins in acute stroke is safe: results of the STARS Randomized Trial. Stroke, 47, 2870–3.Google Scholar
Muir, KW, Lees, KR. (2003). Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst Rev, 3, CD001244.CrossRefGoogle ScholarPubMed
Muscari, A, Puddu, GM, Santoro, N, Serafini, C, Cenni, A, Rossi, V, et al. (2011). The Atorvastatin During Ischemic Stroke Study: a pilot randomized controlled trial . Clin Neuropharm, 34, 141–7.Google Scholar
Narayanan, S, Dave, K, Perez-Pinzon, M. (2013). Ischemic preconditioning and clinical scenarios. Curr Opin Neurol, 26, 1–7.Google Scholar
O’Collins, VE, Macleod, MR, Donnan, GA, Horky, LL, van der Worp, BH, Howells, DW. (2006). 1,026 experimental treatments in acute stroke. Ann Neurol, 59, 467–77.Google Scholar
Ovbiagele, B, Kidwell, CS, Starkman, S, Saver, JL. (2003). Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke. Curr Treat Options Neurol, 5, 367–75.Google Scholar
Paciaroni, M, Bogousslavsky, J. (2011). Trafermin for stroke recovery: is it time for another randomized clinical trial? Expert Opin Biol Ther, 11, 1533–41.Google Scholar
Ricci, S, Celani, MG, Cantisani, TA, Righetti, E. (2012). Piracetam for acute ischaemic stroke. Cochrane Database Syst Rev, 9. CD000419. doi:10.1002/14651858.CD000419.pub3.Google Scholar
Romanos, E, Planas, AM, Amaro, S, Chamorro, A. (2007). Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke . J Cereb Blood Flow Metab, 27, 14–20.Google Scholar
Saxena, R, Wijnhoud, AD, Carton, H, Hacke, W, Kaste, M, Przybelski, RJ, et al. (1999). Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. Stroke, 30, 993–6.Google Scholar
Saver, JL. (2008). Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair. Rev Neurol Dis, 5, 167–77.Google Scholar
Saver, JL Goyal, M, van der Lugt, A, Menon, BK, Majoie, CB, Dippel, DW, et al. (2016). Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. JAMA, 316, 1279–88.Google Scholar
Saver, JL, Starkman, S., Eckstein, M, Stratton, SJ, Pratt, FD, Hamilton, S, et al. (2015). Prehospital use of magnesium sulfate as neuroprotection in acute stroke. N Engl J Med, 372, 528–36.Google Scholar
Secades, JJ, Alvarez-Sabín, J, Castillo, J, Diez-Tejedor, E, Martinez-Vila, E, Rios, J, et al. (2016). Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. J Stroke Cerebrovasc Dis, 25,1984–96.Google Scholar
Sekerdag, E, Solaroglu, I, Gursoy-Ozdemir, Y. (2018). Cell death mechanisms in stroke and novel molecular and cellular treatment options. Curr Neuropharmacol, 16(9), 1396–1415. doi:10.2174/1570159X16666180321100439.Google Scholar
Wan, YH, Nie, C, Wang, HL, Huang, CY. (2014). Therapeutic hypothermia (different depths, durations, and rewarming speeds) for acute ischemic stroke: a meta-analysis. J Stroke Cerebrovasc Dis, 23, 2736–47CrossRefGoogle ScholarPubMed
Wang, Y, Reis, C, Applegate, R 2nd, Stier, G, Martin, R, Zhang, JH. (2015). Ischemic conditioning-induced endogenous brain protection: applications pre-, per- or post-stroke. Exper Neurol, 272, 26–40.Google Scholar
Wang, Y, Yoshimura, R, Manabe, H, Schretter, C, Clarke, R, Cai, Y, et al. (2014). Trans-sodium crocetinate improves outcomes in rodent models of occlusive and hemorrhagic stroke. Brain Res, 1583, 245–54.Google Scholar
Wang, Z, Lin, Y, Liu, Y, Chen, Y, Wang, B, Li, C, et al. (2016). Serum uric acid levels and outcomes after acute ischemic stroke. Mol Neurobiol, 53, 1753–9.Google Scholar
Willmot, M, Ghadami, A, Whysall, B, Clarke, W, Wardlaw, J, Bath, PM. (2006). Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension, 47, 1209–15.Google Scholar
Yaghi, S, Elkind, MSV. (2016). Lipid control and beyond: current and future indications for statin therapy in stroke. Curr Treat Options Cardio Med, 18, 27. doi:10.1007/s11936-016–0448-8.Google Scholar
Yang, J, Cui, C, Li, J, Zhang, C, Zhang, J, Liu, M. (2015). Edaravone for acute stroke: Meta-analyses of data from randomized controlled trials. Devel Neurorehab, 18, 330–5.Google ScholarPubMed
Yoshimura, S, Uchida, K, Daimon, T, Takashima, R, Kimura, K, Morimoto, T; ASSORT Trial Investigator. (2017). Randomized controlled trial of early versus delayed statin therapy in patients with acute ischemic stroke: ASSORT Trial. Stroke, 48, 3057–63.Google Scholar
Zhang, J, Yang, J, Zhang, C, Jiang, X, Zhou, H, Liu, M. (2012). Calcium antagonists for acute ischemic stroke. Cochrane Database Syst Rev, 5. CD001928. doi:10.1002/14651858.CD001928.pub2.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×